CGM Technology and Digital Health
Click here to download the summary from this live event or watch the webinar video archive below.
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
Dexcom G7 is now cleared in the U.S. for people with all Types of diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution. The next-generation real-time continuous glucose monitoring system demonstrates comparable accuracy to previous versions while offering a smaller sensor and enhanced ease-of-use features.
Learn MoreLilly’s new Tempo personalized diabetes management platform features a reusable medical device that attaches to prefilled, disposable insulin pens and sends dose-related data to a compatible app. Patients attach the Tempo Smart Button to the Tempo Pen to send insulin-dose information to TempoSmart. Capturing the data facilitates medication reminders, personalized education resources, and feedback on blood glucose levels, realized through integration with compatible technologies, including real-time continuous glucose monitoring (RT-CGM) via the Dexcom G6. Labeled a “diabetes ecosystem” solution, the fully integrated combination of devices, drugs, and technology offers an opportunity to adapt to each patient’s unique needs in diabetes management while providing value to both physician and payer stakeholders at the same time.
Learn More
Expert: Thomas Grace, MD, Medical Director at the Blanchard Valley Diabetes Center
Summary: This video interview describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in a clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
CME INFORMATION
Release Date: 9/15/2022
CE Expired
TARGET AUDIENCE
This activity is intended for primary care physicians and internal medicine physicians.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Data supporting use of rtCGM in practice
- Have greater competence related to Implementing practical strategies for
using rtCGM in practice
The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.
Learn More